Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome a narrative review

Annals of Internal Medicine

Volumn 164, Issue 9, 2016, Pages 600-607

  Navarese, Eliano P ^a   Kołodziejczak, Michalina ^a   Kereiakes, Dean J ^b   Tantry, Udaya S ^c   O'connor, Christopher ^c   Gurbel, Paul A ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 MONOCLONAL ANTIBODY; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; FIBRINOLYTIC AGENT; IMMUNOLOGIC FACTOR; LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; ENZYME BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; LIPID METABOLISM; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TIME TO TREATMENT; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; IMMUNOLOGY; PLAQUE, ATHEROSCLEROTIC; TIME FACTOR;

ACUTE CORONARY SYNDROME; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LIPOPROTEINS, LDL; PLAQUE, ATHEROSCLEROTIC; PROPROTEIN CONVERTASE 9; RECURRENCE; TIME FACTORS;

EID: 84982116534     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2994     Document Type: Review

References (60)

1. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35. [PMID: 21247313] doi:10.1056/NEJMoa1002358.
2. Fox KA, Anderson FA Jr, Goodman SG, Steg PG, Pieper K, Quill A, et al; GRACE Investigators. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med. 2008;5:580-9. [PMID: 18665136] doi:10.1038/ncpcardio1302.
3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. [PMID: 15007110].
4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001;285: 1711-8. [PMID: 11277825].
5. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: A meta- Analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814-21. [PMID: 17000936].
6. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A metaanalysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. [PMID: 21067804] doi:10.1016/S0140-6736(10)61350-5.
7. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta- Analysis. Ann Intern Med. 2015;163:40-51. [PMID: 25915661] doi:10.7326/M14-2957.
8. Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, et al. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab [Letter]. J Am Coll Cardiol. 2014;64:2299-300. [PMID: 25456764] doi:10.1016/j.jacc.2014.07.995.
9. Virmani R, Burke AP, Farb A. Plaque rupture and plaque erosion. Thromb Haemost. 1999;82 Suppl 1:1-3. [PMID: 10695476].
10. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9:e106294. [PMID: 25180781] doi:10.1371/journal.pone.0106294.
11. Cheng J, Oemrawsingh R, Garcia-Garcia H, Boersma E, Van Geuns R, Serruys P, et al. PCSK9 in relation to coronary plaque inflammation and cardiovascular outcome. In: Cheng JM, Boersma H. Coronary Artery Disease: From Atherosclerosis to Cardiogenic Shock. Rotterdam, the Netherlands: Erasmus University Rotterdam; 2015:221-38.
12. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis [Letter]. Int J Cardiol. 2014;174:863-4. [PMID: 24801085] doi:10.1016/j.ijcard.2014.04.224.
13. Navarese EP, Kołodziejczak M, Dimitroulis D, Wolff G, Busch HL, Devito F, et al. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the- Art and clinical implications. Eur Heart J Cardiovasc Pharmacother. 2016;2:44-53.
14. Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107:556-67. [PMID: 26092101] doi:10.1093/cvr/cvv178.
15. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9- caspase3 pathway. Mol Cell Biochem. 2012;359:347-58. [PMID: 21847580] doi:10.1007/s11010-011-1028-6.
16. Shen L, Peng HC, Nees SN, Zhao SP, Xu DY. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Lett. 2013; 587:1271-4. [PMID: 23499248] doi:10.1016/j.febslet.2013.02.027.
17. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30:931-8. [PMID: 22825241] doi:10.3892/ijmm.2012.1072.
18. Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1: A001651. [PMID: 20457564] doi:10.1101/cshperspect.a001651.
19. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-κB and its inhibitor, I-κB. J Biol Chem. 2000;275:883-9. [PMID: 10625622].
20. Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH. The NFκB inhibitory peptide, IκBa, prevents human vascular smooth muscle proliferation. Ann Thorac Surg. 1999;67:1227-31. [PMID: 10355388].
21. Zuckerbraun BS, McCloskey CA, Mahidhara RS, Kim PK, Taylor BS, Tzeng E. Overexpression of mutated IκBa inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J Vasc Surg. 2003;38:812-9. [PMID: 14560235].
22. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004; 110:1678-85. [PMID: 15353494].
23. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoEdeficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656-60. [PMID: 12615675].
24. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol. 2003;163:1117-25. [PMID: 12937153].
25. Whitman SC, Ravisankar P, Daugherty A. IFN-γ deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res. 2002;22:661-70. [PMID: 12162876].
26. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-γ enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000;157:1819-24. [PMID: 11106554].
27. Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Mehta JL. Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. Sci Rep. 2013;3:1077. [PMID: 23326634] doi:10.1038/srep01077.
28. Ding Z, Liu S, Wang X, Dai Y, Khaidakov M, Deng X, et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res. 2014;103: 619-28. [PMID: 24776598] doi:10.1093/cvr/cvu114.
29. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220:381-6. [PMID: 22176652] doi:10.1016/j.atherosclerosis.2011.11.026.
30. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283: 2363-72. [PMID: 18039658].
31. Tsimikas S, Witztum JL. Measuring circulating oxidized lowdensity lipoprotein to evaluate coronary risk [Editorial]. Circulation. 2001;103:1930-2. [PMID: 11306518].
32. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73-7. [PMID: 9052782].
33. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-60. [PMID: 11306523].
34. Kühnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55:2103-12. [PMID: 25139399] doi:10.1194/jlr.M051326.
35. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: Where are we now? J Am Coll Cardiol. 2013;62:1541-51. [PMID: 23973684] doi:10.1016/j.jacc.2013.07.043.
36. Orthner CL, Rodgers GM, Fitzgerald LA. Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factor- B in TF induction by diverse agonists. Blood. 1995;86:436-43. [PMID: 7605983].
37. Zhang Y, Liu J, Li S, Xu RX, Sun J, Tang Y, et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently upregulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192. [PMID: 25519174] doi:10.1186/1471-2261-14-192.
38. Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014; 32:297-301. [PMID: 25256660] doi:10.1111/1755-5922.12093.
39. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J AmColl Cardiol. 2012;60:1888-98. [PMID: 23083772] doi:10.1016/j.jacc.2012.08.986.
40. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, et al. Meta- Analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113:1753- 64. [PMID: 24792742] doi:10.1016/j.amjcard.2014.02.034.
41. Navarese EP, De Servi S, Gibson CM, Buffon A, Castriota F, Kubica J, et al. Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: A meta- Analysis of randomized studies. QJM. 2011;104:193-200. [PMID: 21262739] doi:10.1093/qjmed/hcq258.
42. Sciahbasi A, Andreotti F, De Cristofaro R, Fischetti D, Leone AM, Schiavoni G, et al. Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. J Thromb Thrombolysis. 2002;14:131-8. [PMID: 12714832].
43. Fischetti D, Sciahbasi A, Leone AM, Niccoli G, Schiavoni G, Trani C, et al. Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions. J Thromb Thrombolysis. 2000;10:265-9. [PMID: 11122547].
44. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682-9. [PMID: 25440796] doi:10.1016/j.ahj.2014.07.028.
45. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99. [PMID: 25773378] doi:10.1056/NEJMoa1501031.
46. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001;947:199-205. [PMID: 11795267].
47. Pawlowska Z, Swiatkowska M, Krzeslowska J, Pawlicki L, Cierniewski CS. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis. 1993;103:13-20. [PMID: 8280181].
48. Naseem KM, Goodall AH, Bruckdorfer KR. Differential effects of native and oxidatively modified low-density lipoproteins on platelet function. Platelets. 1997;8:163-73. [PMID: 20297939] doi:10.1080/09537109709169333.
49. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086-95. [PMID: 17721545].
50. Korporaal SJ, Van Eck M, Adelmeijer J, Ijsseldijk M, Out R, Lisman T, et al. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2007;27:2476-83. [PMID: 17761940].
51. Akkerman JW. From low-density lipoprotein to platelet activation. Int J Biochem Cell Biol. 2008;40:2374-8. [PMID: 18468940] doi:10.1016/j.biocel.2008.04.002.
52. Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood. 2015;125:2693-703. [PMID: 25710879] doi:10.1182/blood-2014-05-574491.
53. Li S, Zhu CG, Guo YL, Xu RX, Zhang Y, Sun J, et al. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. J Atheroscler Thromb. 2015;22:76-84. [PMID: 25185779] doi:10.5551/jat.25841.
54. Xu H, Li H, Liu J, Zhu D, Wang Z, Chen A, et al. Meta- Analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014;9:e104608. [PMID: 25111308] doi:10.1371/journal.pone.0104608.
55. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279: 50630-8. [PMID: 15385538].
56. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649-62. [PMID: 25778403] doi:10.1074/jbc.M114.611988.
57. Fan J, Sun H, Unoki H, Shiomi M, Watanabe T. Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits. Ann N Y Acad Sci. 2001; 947:362-5. [PMID: 11795291].
58. Guler E, Gecmen C, Guler GB, Karaca O, Agus HZ, Gunes HM, et al. Adding lipoprotein(a) levels to the GRACE score to predict prognosis in patients with non-ST elevation acute coronary syndrome. Kardiol Pol. 2013;71:695-701. [PMID: 23907902] doi:10.5603/KP.2013.0156.
59. Ichikawa T, Unoki H, Sun H, Shimoyamada H, Marcovina S, Shikama H, et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol. 2002;160:227-36. [PMID: 11786416].
60. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1, 300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63:1278-88. [PMID: 24509273] doi:10.1016/j.jacc.2014.01.006.